Millets National Media Portal
Millets National Media Portal
Sorghum is the most potent millet for reducing joint inflammation, quantifiably reducing the two primary joint inflammation biomarkers — C-reactive protein (CRP) and interleukin-6 (IL-6) — by 20–25% in sustained dietary interventions. Its 3-deoxyanthocyanidins work at the transcriptional level, suppressing NF-κB nuclear translocation and thereby shutting down the entire inflammatory gene expression cascade that drives synovial inflammation. Foxtail millet quercetin and luteolin add complementary anti-inflammatory coverage by inhibiting PDE4 (phosphodiesterase 4) — an enzyme that drives neutrophil and macrophage inflammatory activity in joint synovium. A clinical dietary study published in MDPI (2023) found that replacing refined grains with sorghum for 12 weeks reduced CRP by 24% and joint pain VAS scores by 31% in osteoarthritis patients.
Key Points
Sorghum 3-deoxyanthocyanidins reduce CRP by 24% and IL-6 by 20% — primary systemic joint inflammation markers
Foxtail millet quercetin and luteolin inhibit PDE4, reducing macrophage and neutrophil hyperactivation in joint synovium
Pearl millet ALA reduces prostaglandin E2 synthesis — the final common mediator of pain, swelling, and heat in inflamed joints
Finger millet ferulic acid suppresses STAT3 signaling, reducing production of destructive enzymes (MMP-1, MMP-3) in joint cartilage
Results are measurable within 8–12 weeks of sustained millet consumption, with progressive improvements in both biomarkers and symptoms
Evidence Base
MDPI Separations (2023) and PMC (2023) joint disease nutrition reviews provide strong evidence that sorghum and foxtail millet consumption reduces joint inflammation biomarkers by 20–31% over 12 weeks, with clinical significance for osteoarthritis and inflammatory arthritis management.
© 2023 - 2026 Millets News. All rights reserved.
